{"entity":{"id":"nct06313086","kind":"trial","name":"DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer","aka":[],"tldr":"A phase 3 trial of Trastuzumab emtansine in her2-positive breast cancer, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting.","summary":"DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer is a phase 3 interventional study registered as NCT06313086 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 442 participants planned, started 2024-03-13 and due to reach its primary completion in 2025-12. Interventions recorded: DP303c, trastuzumab emtansine. Conditions listed: HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06313086","url":"https://clinicaltrials.gov/study/NCT06313086"}],"tags":["ctgov-ingest"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab-emtansine"],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06313086","phase":"3","setting":"A Multicentre, Randomized, Open-label, Controlled Phase Ш Clinical Study to Evaluate the Efficacy and Safety of DP303c Versus Trastuzumab Emtansine in Patients With HER2-positive Advanced Breast Cancer","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","enrolled":442,"outcomes":[]},"route":"/trials/nct06313086/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}]}}